Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

109.80
-0.6684-0.61%
Post-market: 109.76-0.0402-0.04%19:30 EDT
Volume:10.03K
Turnover:1.10M
Market Cap:92.23M
PE:- -
High:111.43
Open:111.43
Low:108.92
Close:110.47
52wk High:126.40
52wk Low:62.72
Shares:840.00K
Float Shares:840.00K
Volume Ratio:1.58
T/O Rate:1.19%
Dividend:0.22
Dividend Rate:0.20%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease

Reuters
·
Sep 22

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Reuters
·
Sep 22

Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease

THOMSON REUTERS
·
Sep 22

Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity

THOMSON REUTERS
·
Sep 22

Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026

THOMSON REUTERS
·
Sep 22

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live
·
Sep 22

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

TIPRANKS
·
Sep 22

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Reuters
·
Sep 22

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS
·
Sep 22

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS
·
Sep 22

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)

TIPRANKS
·
Sep 22

Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 22

Moderna Inc. Stock Climbs 12.3%, Outperforms Peers

Dow Jones
·
Sep 22

Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594

THOMSON REUTERS
·
Sep 21

Sino Biopharmaceutical Stock Rises 8.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 21

Correction to Vertex Material Listing Article on Sept. 17

Dow Jones
·
Sep 21

Amgen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 19

Vertex wins approval for 24/7 underground operations at Reward Gold Mine

TIPRANKS
·
Sep 18

Vortex Energy Moves to Acquire Saskatchewan Meadows Project for Future Energy Storage Potential

TIPRANKS
·
Sep 18